Sugi Predict

Sugi Predict / Compounds / SCHEMBL970995

SCHEMBL970995

SCHEMBL970995

N[C@@H](C=O)[C@@H](OC(=O)c1ccccc1O)[C@H](O)[C@H](O)CO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.38
▸ LMNA P02545 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ HPGD P15428 5/20 0.36
▸ HSD17B10 Q99714 3/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ ADRB2 P07550 1/20 0.35
▸ ADRB1 P08588 1/20 0.35
▸ ADRB3 P13945 1/20 0.35
▸ ALDH1A1 P00352 8/20 0.34
▸ KDM4E B2RXH2 6/20 0.34
▸ MAPT P10636 1/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3259181 0.82 PTGS2 (0.45) TDP1LMNATSHRHPGDHSD17B10
SCHEMBL5012212 0.81 TDP1 (0.41) TDP1LMNATSHRHPGDHSD17B10
SCHEMBL6938579 0.81 TDP1 (0.41) TDP1LMNATSHRHPGDHSD17B10
SCHEMBL28438469 0.78 TDP1 (0.46) TDP1LMNATSHRHPGDHSD17B10
Acetone SCHEMBL2176182 0.78 LMNA (0.41) TDP1LMNATSHRHPGDHSD17B10
SCHEMBL5963748 0.76 TDP1 (0.43) TDP1LMNATSHRHPGDHSD17B10
SCHEMBL5350442 0.76 KIF11 (0.36) TDP1LMNAHPGDHSD17B10ALDH1A1
SCHEMBL28439957 0.76 TDP1 (0.44) TDP1LMNATSHRHPGDHSD17B10
SCHEMBL28437577 0.76 TDP1 (0.44) TDP1LMNATSHRHPGDHSD17B10
SCHEMBL16429713 0.75 USP2 (0.38) TDP1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116143851-A Salicylic acid glucosamine and preparation method and application thereof 蝶泉(广东)生物科技有限公司 2023-05-23 — — CN claimed
US-20170360687-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2017-12-21 — — US claimed
EP-3236922-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2017-11-01 — — EP claimed
WO-2016102702-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2016-06-30 — — WO claimed
US-20110020251-A1 Ultraviolet-Absorbing Compounds AVOCA LLC 2011-01-27 — — US claimed
US-20040228884-A1 Ion-pair delivery system for cosmetic and pharmaceutical compositions GUPTA SHYAM K (US) 2004-11-18 — — US claimed
US-20040156873-A1 Topically Bioavailable Acne and Rosacea Treatment Compositions GUPTA SHYAM K (US) 2004-08-12 — — US claimed
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions GUPTA SHYAM K (US) 2004-05-13 — — US claimed
EP-4464307-A1 COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME MPLUS COSMETICS S.R.L. (IT) 2024-11-20 — — EP disclosed
US-20240374498-A1 COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME MPLUS COSMETICS S.R.L. (IT) 2024-11-14 — — US disclosed
CN-116143851-A Salicylic acid glucosamine and preparation method and application thereof 蝶泉(广东)生物科技有限公司 2023-05-23 — — CN disclosed
CN-116143851-A Salicylic acid glucosamine and preparation method and application thereof 蝶泉(广东)生物科技有限公司 2023-05-23 — — CN disclosed
EP-2691077-B1 SALICYLIC ACID TOPICAL FORMULATION INTEGUMEN IRELAND LTD (IE) 2018-05-09 — — EP disclosed
US-20170360687-A1 SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF L'OREAL (FR) 2017-12-21 — — US disclosed
US-7179477-B2 Cosmetic dermabrasion treatment system GUPTA SHYAM K 2007-02-20 — — US disclosed
WO-2006023710-A2 COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE INFINITY2 HEALTH SCIENCES, INC. (US) 2006-03-02 — — WO disclosed
US-20060039887-A1 Cosmetic or pharmaceutical composition for skin care INFINITY2 HEALTH SCIENCES, INC. 2006-02-23 — — US disclosed
US-20050037038-A1 Cosmetic Dermabrasion Treatment System GUPTA SHYAM K (US) 2005-02-17 — — US disclosed
US-20040228884-A1 Ion-pair delivery system for cosmetic and pharmaceutical compositions GUPTA SHYAM K (US) 2004-11-18 — — US disclosed
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions GUPTA SHYAM K (US) 2004-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions CUTA, HIRA, HARS1 TDP1 3438/4885LMNA 736/4885TSHR 3329/4885
US-20110020251-A1 Ultraviolet-Absorbing Compounds UFM1, UHRF1, CUTA TDP1 2312/4885LMNA 1229/4885TSHR 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.